

CONNECT WITH NATURE

Q1 2022 Earnings Presentation
May 5, 2022



NATURES
SUNSHINE



SAFE HARBOR STATEMENTS



Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements regarding the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to the Company's objectives, plans, strategies and financial results. All statements (other than statements of historical fact) that address activities, events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including the following: adverse impacts of the global COVID-19 pandemic; laws and regulations regarding direct selling may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets; extensive government regulations to which the Company's products, business practices and manufacturing activities are subject; legal challenges to the Company's direct selling program or to the classification of its independent distributors; impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act; the Company's ability to attract and retain independent distributors; the loss of one or more key independent distributors who have a significant sales network; the Company's joint venture for operations in China with Fosun Industrial Co., Ltd.; registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets; cybersecurity threats and exposure to data loss; the storage, processing, and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations; reliance on information technology infrastructure; the effect of fluctuating foreign exchange rates; liabilities and obligations arising from improper activity by the Company's independent distributors; failure of the Company's independent distributors to comply with advertising laws; changes to the Company's independent distributor compensation plans; geopolitical issues and conflicts; negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company's customers to purchase products; risks associated with the manufacturing of the Company's products; uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto; changes in tax laws, treaties or regulations, or their interpretation; actions on trade relations by the U.S. and foreign governments; product liability claims; the sufficiency of trademarks and other intellectual property rights; and our cannabidiol (CBD) product line is subject to varying, rapidly changing laws, regulations, and rules.

These and other risks and uncertainties that could cause actual results to differ from predicted results are more fully detailed under the caption "Risk Factors" in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports filed on Form 10-Q.

All forward-looking statements speak only as of the date of this presentation and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this presentation. Except as is required by law, the Company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this presentation.

Non-GAAP Financial Measures

We have included information which has not been prepared in accordance with generally accepted accounting principles (GAAP), such as information concerning non-GAAP net income and Adjusted EBITDA. We utilize the non-GAAP measures of non-GAAP net income and Adjusted EBITDA in the evaluation of our operations and believe that these measures are useful indicators of our ability to fund our business. These non-GAAP financial measures should not be considered as an alternative to, or more meaningful than, U.S. GAAP net income (loss) as an indicator of our operating performance. Other companies may use the same or similarly named measures, but exclude different items, which may not provide investors with a comparable view of Nature's Sunshine Products' performance in relation to other companies. We have included a reconciliation of Net Income to Adjusted EBITDA, the most comparable GAAP measure. We have also included a reconciliation of GAAP net income to Non-GAAP net income and Non-GAAP Adjusted EPS, in the appendix. We believe presenting the impact of foreign currency fluctuations is useful to investors because it allows a more meaningful comparison of net sales of our foreign operations from period to period. Net sales excluding the impact of foreign currency fluctuations should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.



FEEL THE POWER...



Nature's Sunshine changed the world ~50 years ago as the first company to put herbs into easy-to-take capsules



We sell 700+ products across six different categories around the world



Sophisticated in-house R&D capabilities via owned **Hughes Center for Research & Innovation**



We manufacture most of our products, **ensuring optimal quality and safety**



We are executing a brand pivot supported by important **consumer lifestyle changes**

FIRST QUARTER 2022 FINANCIAL SUMMARY



\$ in millions, except for margin and per share amounts

	Q1 2022	Q1 2021	▲	Q4 (y/y) Commentary
Net Sales	\$110.5	\$102.4	+8%	29% growth in Asia segment drove the increase
Gross Margin	68.8%	73.7%	-4.9%	Increased product reserves due to Ukraine/Russia conflict and reserves in other markets, product mix shift, increased production and transportation costs
SG&A	\$40.6	\$33.6	+21%	Variable service fees in China given strong regional growth, implementation of business transformation and sales growth initiatives in other markets
Operating Income	\$1.3	\$7.6	-83%	Reflects the factors above
Net Income	\$(2.7)	\$4.2	-165%	Reflects the factors above as well as Provision for income taxes of \$3.7M in Q1-22
Diluted EPS	\$(0.15)	\$0.20	-175%	Reflects the factors above
Adj. EBITDA	\$8.2	\$11.6	-29%	Reflects the gross margin and SG&A factors above

¹ See appendix for a reconciliation of non-GAAP terms.

STRONG BALANCE SHEET



Balance Sheet Highlights

- Cash and cash equivalents totaled \$66.5M
- \$2.1M of debt at 3/31/22 vs. \$2.7M at 12/31/21

	As of	
	Mar. 31, 2022	Dec. 31, 2021
<i>(\$ in millions)</i>		
Cash and Cash Equivalents	\$ 66.5	\$ 86.2
Receivables	7.3	8.9
Total Assets	238.7	258.9
Debt	2.1	2.7
Total Liabilities	88.9	97.5
Total Stockholders' Equity	149.8	161.4

NET SALES BY OPERATING SEGMENT




Net Sales by Operating Segment (Amounts in Thousands)					
	Q1 2022	Q1 2021	% Change	Impact of Currency Exchange	% Change Excl. Impact of Currency
Asia	\$ 46,110	\$ 35,755	29.0%	\$ (1,850)	34.1%
Europe	21,777	22,200	(1.9)	(554)	0.6
North America	35,981	37,762	(4.7)	(1)	(4.7)
Latin America and Other	<u>6,626</u>	<u>6,704</u>	(1.2)	(62)	(0.2)
	<u>\$ 110,494</u>	<u>\$ 102,421</u>	7.9%	<u>\$ (2,467)</u>	10.3%

HISTORICAL FINANCIAL PERFORMANCE



Revenue

\$ in Millions




Revenue Accelerant Opportunities

- Stronger regional-focused sales teams
- International market growth (China, Western Europe)
- Increased productivity of customers & distributors
- New products

Adj. EBITDA¹

\$ in Millions



Margin Drivers

- Drive surplus manufacturing efficiencies
- Improved manufacturing costs
- Continue SG&A cost efficiencies

¹ See appendix for a reconciliation of this non-GAAP term.

OUR OPERATIONAL EXECUTION



Brand Power



Revitalized our brand with new packaging & advertising

Field Energy

● SUBSCRIBE & THRIVE
\$22.95
SAVE 25%
~~\$30.60~~

- FREE Shipping (1 per month)
- FREE 1-Year Premium Membership
- One-click pause or cancel
- Choose your schedule and frequency
- Cancel anytime

Frequency

Offered new suite of business tools, services & customer-focused rewards

Digital First



Introduced new website functionality to move from transactional to personal relationships

Manufacturing Inc.



Secured USDA and ISO 9001 certifications, enhancing our industry-leading advantage

The Right Stuff



Streamlined global business processes to improve overall cost and efficiency

2022 PRIORITIES



OUR RESPONSE TO TODAY'S CONSUMER DEFINES OUR VISION



Vision

SHARE THE HEALING
POWER OF NATURE,
WITH EVERYONE.

How?



Offer specialty, time-tested products, proven by health practitioners



Create lifestyle branding and storytelling




Leverage websites, e-commerce and digital marketing to drive customer loyalty



Deliver customized experiences to encourage trial and repeat purchases

OUR FIVE GLOBAL GROWTH STRATEGIES



CAPITAL ALLOCATION PLAN



**Significant cash flow
has enabled the
investment and growth
of the business to date**

**Well-positioned to
return a portion of this
cash to shareholders**

Capital Allocation Plan

Special cash dividend of \$1.00 per share paid to shareholders in April 2021

\$8M in shares repurchased at an average cost of \$17.74 per share in Q1 2022 – \$29.6M remaining in share repurchase program as of March 31, 2022

Ongoing investment in organic growth opportunities

Strategic M&A



CONTACT US

Investor Relations Contact

Cody Slach

Senior Managing Director,
Gateway Group, Inc.



(949) 574-3860



NATR@gatewayir.com

APPENDIX





ADJUSTED EBITDA RECONCILIATION

(Amounts in thousands)
(Unaudited)

	Three Months Ended March 31,	
	2022	2021
Net income (loss)	\$ (2,686)	\$ 4,152
Adjustments:		
Depreciation and amortization	2,766	2,736
Share-based compensation expense	801	1,005
Other loss, net*	314	1,933
Provision for income taxes	3,681	1,550
Other adjustments (1)	3,307	175
Adjusted EBITDA	\$ 8,183	\$ 11,551
(1) Other adjustments		
Inventory reserve related to Russia/Ukraine war**	\$ 3,050	\$ —
Capital allocation and other expenses	—	175
Restructuring and other related expenses	257	—
Total adjustments	\$ 3,307	\$ 175

*Other (income) loss, net is primarily comprised of foreign exchange losses, interest income, and interest expense.

** As a result of the conflict between Russia and Ukraine, the Company has recorded a non-cash reserve above and beyond usual operating levels based on its estimates of actual future inventory consumption and operating results

ADJUSTED EBITDA RECONCILIATION



RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA

	2018	2019	2020	2021	Q1'22 TTM
Net Income (loss)	\$ (1,202)	\$ 6,929	\$ 22,958	\$ 30,207	\$ 23,369
Adjustments:					
Depreciation and amortization	9,806	10,599	10,743	11,162	11,192
Share-based compensation expense	2,170	2,120	3,787	3,731	3,527
Other (income) loss, net*	2,151	483	(1,339)	2,848	1,229
Provision (benefit) for income taxes	4,402	8,713	(137)	1,615	3,746
Other adjustments (1)	252	2,375	173	(143)	2,989
Adjusted EBITDA	<u>\$ 17,579</u>	<u>\$ 31,219</u>	<u>\$ 36,185</u>	<u>\$ 49,420</u>	<u>\$ 46,052</u>
(1) Other Adjustments					
Capital allocation and other unusual expenses	-	-	-	265	90
Inventory reserve related to Russia/Ukraine war**	-	-	-	-	3,050
CEO transition	2,518	-	-	-	-
Restructuring related expenses	1,525	2,375	808	369	626
Gain on sale of properties	(3,791)	-	-	-	-
VAT Refund	-	-	(635)	(777)	(777)
Total adjustments	<u>\$ 252</u>	<u>\$ 2,375</u>	<u>\$ 173</u>	<u>\$ (143)</u>	<u>\$ 2,989</u>

*Other (income) loss, net is primarily comprised of foreign exchange losses, interest income, and interest expense.

** As a result of the conflict between Russia and Ukraine, the Company has recorded a non-cash reserve above and beyond usual operating levels based on its estimates of actual future inventory consumption and operating results